Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.

ABSTRACT:

Background

The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice.

Methods

To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16^th of May 2023, with the aim of establishing best practice guidelines.

Results

Using

SUBMITTER: Tsoulaki O 

PROVIDER: S-EPMC11183136 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature